Pseudovirus News and Research

RSS

Cell-based assay highlights differences in antibody neutralizing capacity for SARS-CoV-2 variants

A recent study by scientists at Celentyx Ltd, the University of Birmingham, and the University of Warwick and posted to the bioRxiv* preprint server illustrated a cell-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein attachment assay.

28 Jun 2022

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

Researchers presented the PREVENT-19 phase 3 trial findings on the effectiveness of the NVX-CoV2373 adjuvanted, recombinant S nanoparticle vaccine.

27 Jun 2022

Antigenic differences between early SARS-CoV-2 variants

Researchers used antigenic cartography to quantify and visualize antigenic differences between multiple SARS‐CoV‐2 variants.

27 Jun 2022

Fragment crystallizable-altered COVID-19 antibodies efficacious across two animal models

A recent article posted to the bioRxiv* preprint server identified numerous efficacious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies from convalescent SARS-CoV-2 patients.

23 Jun 2022

Study finds traditional African drug inhibits growth of SARS-CoV-2 infection

Researchers evaluated the efficacy of PHELA, a traditional African drug, against SARS-CoV-2 in vitro.

21 Jun 2022

Type I interferons play crucial role in fending off SARS-CoV-2

Researchers investigated whether individuals with breakthrough infections of COVID-19 pneumonia demonstrated normal antibody responses to vaccinations and whether they harbored type I interferon-neutralizing auto-antibodies.

16 Jun 2022

Animal study suggests intranasal COVID vaccine delivery more efficient than intramuscular

In a recent study published in the journal PNAS, researchers demonstrated higher comparative efficacy of the intranasal (IN) route of coronavirus disease 2019 (COVID-19) vaccine administration versus intramuscular route in mice.

12 Jun 2022

Super-immunity in a camelid extensively immunized with the SARS-CoV-2 receptor-binding domain

A recent study published in Cell Reports reported the development of pan-sarbecovirus nanobodies (psNbs).

10 Jun 2022

The effect of Omicron breakthrough infection on the magnitude and breadth of serum neutralizing activity and memory B cells among BNT162b2 vaccinees

Researchers evaluated the impact of breakthrough infections with SARS-CoV-2 Omicron BA.1 sublineage on SARS-CoV-2 variants of concern neutralization and memory B lymphocytes formation among BNT162b2 vaccinees.

7 Jun 2022

De novo-designed mini-protein against SARS-CoV-2

Researchers characterized truncated forms of LCB1, a de novo-designed mini-protein, against SARS-CoV-2.

7 Jun 2022

Omicron lineage spike proteins use ACE2 receptors more efficiently

A recent study posted to the bioRxiv* preprint server demonstrated various traits, including the entry pathways and sensitivity to vaccination-elicited antibody responses by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants.

7 Jun 2022

HIV research enables knowledge transfer for improved COVID-19 response

Global virology and immunology networks that were originally developed for HIV vaccine research were rapidly adapted to study COVID-19.

31 May 2022

Exploring virological profiles of recently emerged SARS-CoV-2 Omicron variants

Researchers explored the virological profiles of novel SARS-CoV-2 Omicron variants.

30 May 2022

Continuous evolution of SARS-CoV-2 Omicron variant yielding immune evasive subvariants

Researchers reported findings of a systematic antigenic analysis of the circulating SARS-CoV-2 Omicron subvariants such as BA.2.12.1, BA.4, and BA.5.

30 May 2022

Direct comparison of immune memory responses to four COVID-19 vaccines

Researchers evaluated host immune responses to four COVID-19 vaccines representing three different vaccine technology platforms, focusing on immune memory responses.

30 May 2022

Pediatric patients with prior COVID-19 or MIS-C are not protected against Omicron

Research drawing on the national Overcoming COVID-19 study, led by Boston Children's Hospital, and the hospital's own Taking On COVID-19 Together Group provides evidence that children who previously had COVID-19 (or the inflammatory condition MIS-C) are not protected against the newer Omicron variant.

27 May 2022

Hamster contact exposure challenge model assesses protection conferred by SARS-CoV-2 vaccination or prior infection against reinfection

Researchers assessed the neutralization efficacy of a saRNA vaccine targeting SARS-CoV-2 S protein against reinfection among hamsters with prior vaccination or infection.

24 May 2022

Pseudovirus News and Research

Cell-based assay highlights differences in antibody neutralizing capacity for SARS-CoV-2 variants

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

Antigenic differences between early SARS-CoV-2 variants

Fragment crystallizable-altered COVID-19 antibodies efficacious across two animal models

Study finds traditional African drug inhibits growth of SARS-CoV-2 infection

Type I interferons play crucial role in fending off SARS-CoV-2

Animal study suggests intranasal COVID vaccine delivery more efficient than intramuscular

Super-immunity in a camelid extensively immunized with the SARS-CoV-2 receptor-binding domain

The effect of Omicron breakthrough infection on the magnitude and breadth of serum neutralizing activity and memory B cells among BNT162b2 vaccinees

De novo-designed mini-protein against SARS-CoV-2

Omicron lineage spike proteins use ACE2 receptors more efficiently

HIV research enables knowledge transfer for improved COVID-19 response

Exploring virological profiles of recently emerged SARS-CoV-2 Omicron variants

Continuous evolution of SARS-CoV-2 Omicron variant yielding immune evasive subvariants

Direct comparison of immune memory responses to four COVID-19 vaccines

Pediatric patients with prior COVID-19 or MIS-C are not protected against Omicron

Hamster contact exposure challenge model assesses protection conferred by SARS-CoV-2 vaccination or prior infection against reinfection

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

SARS-CoV-2 Omicron subvariants are increasingly escaping immunity

Neutralizing antibody responses induced by COVID-19 vaccines against SARS-CoV-2 variants

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News